Phase 2 trial of RLS-0071 : ReAlta’s innovative approach to treating rare newborn disease
ReAlta Life Sciences, Inc., a clinical mid-stage biotech company focusing on rare life-threatening diseases, has announced the commencement of dosing in a Phase 2 clinical trial for RLS-0071. The investigational new drug aims to evaluate safety and efficacy for treating hypoxic ischemic encephalopathy (HIE) in newborns, offering a new avenue for addressing an urgent medical […]